Fig. 6: CPT1A levels correlate with PD-1 mAb efficacy in melanoma.
From: Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma
a, Summary of the in-house melanoma cohort. b, Heatmap showing the clinical characteristics of the in-house melanoma cohort treated with anti-PD-1 mAb. Each column represents an individual patient. Rs include those with complete response (CR), partial response (PR) or stable disease (SD) > 6 months, whereas NRs include those with SD ≤ 6 months or progressive disease (PD). PFS, 0 means progression free, 1 means progression or death; OS: 0 means alive, 1 means death. c, Representative fluorescence images showing CPT1A and PD-L1 expression in patients with distinct therapy responses. d, Heatmap illustrating a significant negative correlation between CPT1A and PD-L1 expression (Spearman’s rank correlation). e, Box plots showing differential CPT1A and PD-L1 expression between R (n = 26 patients) and NR (n = 19 patients) groups. f, Univariate Cox’s regression analysis of OS (top) and PFS (bottom) based on CPT1A and PD-L1 expression (n = 45 patients). g,h, Kaplan–Meier plots demonstrating the synergistic effects of CPT1A and PD-L1 expression on PFS (g) and OS (h). i, Proportions of patients with different immunotherapy responses in the cohort (n = 45 patients). j, Schematic diagram of summary. The accumulation of succinate or oxoglutarate-derived succinyl-CoA mediates PD-L1 succinylation, serving as an indicator of the intrinsic lysosomal degradation of PD-L1. CPT1A, as a succinyltransferase that controls the succinylation of PD-L1, was identified as a new target for melanoma therapy and may be used in combination with PD-L1 as a marker to predict the effect of anti-PD-1 therapy. For details on visualization, statistics and reproducibility, see Methods. Note, n refers to independent biological replicates. HR, hazard ratio. Schematic in j created using BioRender.com.
